Theme

Field-oriented
Sessions

Session Title

Preclinicalmodels/Experimental
therapy/drug discovery

Presentation
No.

Abstract
No.

Lecture title

SpeakerCountry

MOD-IS-01

IS-19

In Silico Drug Screening and System Biology Approach in Drug Repurposing

Ching Lau

USA

MOD-O-02

MODL-20

A biobank of ~100 patient-derived models representing biological heterogeneity anddistinct therapeutic dependencies in paediatric high grade glioma and DIPG

Diana Carvalho

UK

MOD-O-03

MODL-25

Replication repair deficient mouse models provide insight on hypermutant brain
tumours, mechanisms of immune evasion, and combinatorial immunotherapy

Melissa Galati

CanadaMOD-O-04

MODL-09

Feasibility of acute slice culture-single cell sequencing drug screening as a tool toselect therapy for children with relapsed brain tumors

Bradley Gampel

USA

MOD-O-05

MODL-11Comparison of human & murine PA/PXA characteristics

Alexander Sommerkamp

Germany

MOD-P-06

MODL-26

Children’s Brain Tumor Network: accelerating research through collaboration and openAngela Waanders
scienceUSA

MOD-P-07

MODL-30

Dissecting the role of multi-ciliogenesis network in choroid plexus tumor

Tasneem ZahranUSAMOD-P-08

MODL-04

Modeling CNS HGNET-BCOR pathogenesis using neural stem cells

Satoshi Nakata

MOD-P-09

MODL-14

Small molecule targeting of oncogenic FGF2-FGFR signaling in brain tumors

Martin Baumgartner

Switzerland

MOD-P-10

MODL-28

Immune priming with interferon-γ combined with epigenetic modulation in pediatricbrain tumors

Erin Crotty

USA

MOD-P-11

MODL-03

Adapting palbociclib for medulloblastoma therapy by improving drug delivery andaddressing resistanceTaylor Dismuke

USA

MOD-P-12

MODL-19

DIPG harbour alterations targetable by MEK inhibitors, with acquired resistancemechanisms overcome by combinatorial up- or down-stream inhibition

Elisa Izquierdo

UKMOD-P-13

MODL-21

Integrative approaches in functional genomics to identify genetic dependencies inpediatric brain cancer

Claire Sun

Australia

MOD-P-14

MODL-22Developing a real-time personalized drug testing platform for pediatric CNS cancers

Chiara Cianciolo Cosentino

Switzerland

MOD-P-15

MODL-23

DNA methylation and copy number variation profile for characterization of pediatricbrain tumor primary cell lines

Evelina Miele

Italy

MOD-P-16

MODL-08

Optimization of a novel local delivery system for the treatments of supratentorial
ependymoma

Lisa Ruff

UK

MOD-P-17

MODL-31

Radiation-derived treatment-resistant PDX and cell culture models recapitulate thecharacteristics of matched primary/recurrent pediatric high-grade glioma

Adam GreenUSA

MOD-P-18

MODL-01

Safety in concomitant use of MEK and BRAF inhibitors with bevacizumab

Shelby Winzent

USA

MOD-P-19

MODL-16

Abemaciclib, a selective CDK4/6 inhibitor, restricts growth of pediatric glial-lineage
tumors in vitro and in vivo

Muh-Lii LiangTaiwan

MOD-P-20

MODL-17

SHP2 inhibitors show activity against NF1-deficient gliomas and enhance MAPK
pathway inhibition in BRAF-V600E mutant gliomas

Daniel Muldoon

USA

MOD-P-21

MODL-02

Targeting replication stress in pediatric brain tumors

Sonja Krausert

Germany

MOD-P-22

MODL-06

Preclinical efficacy of the imipridone ONC-206 against medulloblastoma

Tobey MacDonald

USA

MOD-P-23

MODL-12Development of a novel immunocompetent mouse model for diffuse intrinsic pontine
gliomaMaggie Seblani

USA

MOD-P-24

MODL-27

MEK inhibition with trametinib slows progression of medulloblastoma and atypicalteratoid rhabdoid tumor in orthotopic xenograft murine model

Sujata Mushrif

India

MOD-P-25

MODL-29

Evaluating tumor-immune interactions in mouse models of diffuse intrinsic pontine
gliomaTimothy Phoenix

USA

MOD-P-26

MODL-13

Genetically engineered pig model of rhabdoid tumor predisposition syndrome-1

Brian NaUSA

MOD-P-27

MODL-24

An organotypic chunk culture technique to study disease mechanism and develop
targeted therapeutics for pediatric adamantinomatous craniopharyngioma

Oscar Chatain

USA

MOD-P-28

MODL-15

The combination treatment of PARP inhibitor and TMZ, or DAG willbe promisingtreatment in SF8628.

Shigeo Ohba

Japan